Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor

Abstract

The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided.

1 .- 17 . (canceled) 
     
     
         18 . A method of diagnosing a condition associated with lysyl oxidase-like-2 (LOXL2) comprising: assessing a level of LOXL2 in a sample of a subject by contacting said sample with an isolated antibody that specifically binds to an epitope defined by amino acids 325 through 434 of the sequence depicted in  FIG. 1  and set forth in SEQ ID NO: 1, wherein a change in level of LOXL2 in the sample in comparison with a reference sample indicates the presence of the condition associated with LOXL2. 
     
     
         19 . The method of  claim 18 , wherein said condition associated with LOXL2 is a tumor, a metastasis, angiogenesis, or fibrosis. 
     
     
         20 . The method of  claim 19 , wherein an increase in LOXL2 levels in the sample in comparison with a reference sample indicates the presence of a tumor or metastasis thereof, or an increase in tumor or metastatic growth. 
     
     
         21 . The method of  claim 20 , wherein the reference sample is a sample taken from the subject at an earlier time point or from unaffected tissue of the same type, or is a sample from another individual. 
     
     
         22 . The method of  claim 18 , wherein the antibody is detectably labeled. 
     
     
         23 .- 32 . (canceled) 
     
     
         33 . The method of  claim 18 , wherein the epitope comprises amino acids within the sequence TPAMGLQKK (SEQ ID NO:2). 
     
     
         34 . The method of  claim 18 , wherein the antibody binds the epitope with an affinity of from about 10 7  M −1  to about 10 12  M −1 . 
     
     
         35 . The method of  claim 18 , wherein the antibody comprises a heavy chain, and wherein the heavy chain of the antibody is of the isotype IgG1, IgG2, IgG3, or IgG4. 
     
     
         36 . The method of  claim 18 , wherein the antibody is a Fv, scFv, Fab, F(ab′)2, or Fab′. 
     
     
         37 . The method of  claim 18 , wherein the antibody is humanized. 
     
     
         38 . The method of  claim 18 , wherein the antibody is chimeric. 
     
     
         39 . The method of  claim 18 , wherein the antibody comprises a covalently linked moiety selected from the group consisting of a non-peptide synthetic polymer, a lipid, a fatty acid, a polysaccharide, a carbohydrate, or a contrast agent. 
     
     
         40 . The method of  claim 18 , wherein the synthetic polymer is poly(ethylene glycol) polymer. 
     
     
         41 . The method of  claim 18 , wherein the antibody is immobilized on a solid support. 
     
     
         42 . A kit for diagnosing a condition associated with LOXL2 comprising a composition comprising an isolated antibody that specifically binds to an epitope defined by amino acids 325 through 434 of the sequence depicted in  FIG. 1  and set forth in SEQ ID NO: 1. 
     
     
         43 . The kit of  claim 42 , wherein said condition associated with LOXL2 is a tumor, a metastasis, angiogenesis, or fibrosis. 
     
     
         44 . The kit of  claim 42 , wherein the LOXL2 binding agent comprises a detectable label.